Go to Health Care Provider version
| Diagnosis | Relapsed or refractory hepatoblastoma or rhabdomyosarcoma (RMS) | Study Status | Open |
| Phase | I/II |
| Age | 1 Month to 17 Years | Randomisation | NO |
| Line of treatment | Disease relapse or progression |
| Routes of Treatment Administration | Biological: Patritumab Deruxtecan (IV)
Other names - MK-1022, HER3-DXd, U3-1402 |
| Last Posted Update | 2026-03-27 |
| ClinicalTrials.gov # | NCT06941272 |
International Sponsor
Merck Sharp & Dohme LLCPrincipal Investigators for Canadian Sites
Montreal Children's Hospital - Dr. Catherine Vézina
The Hospital for Sick Children - Dr. Daniel MorgensternCentres
Medical contact
Clinical Research Unit
Social worker/patient navigator contact
Clinical Research Unit
Clinical research contact
Stephanie Badour
Study Description
Researchers are looking for new ways to treat children with hepatoblastoma or rhabdomyosarcoma (RMS) that has come back or not responded to other treatment. This study treatment investigating whether HER3-DXd (also known as MK-1022 or patritumab deruxtecan) is safe, effective and how it is absorbed.
Inclusion Criteria
- Children and teens (between 1 month to 17 years old) with one of these cancers: hepatoblastoma or rhabdomyosarcoma
- The cancer must have come back or not responded to treatment
- Participants must have already tried at least one treatment before and don’t have another good standard option left.
- Side effects from past treatments should be mild or gone
- Children who had hepatitis B or C can join if the virus is under control with medicine and no virus is showing up in tests.
Other inclusion and exclusion criteria may apply and will be discussed with you by the study team.
